How to Get Wegovy in Florida

What Is Wegovy and Why Does It Require a Prescription?

Wegovy is the brand name for semaglutide 2.4 mg, a glucagon-like peptide-1 (GLP-1) receptor agonist that the FDA approved in June 2021 for chronic weight management in adults with obesity or overweight plus at least one weight-related condition [1]. The drug mimics native GLP-1, slowing gastric emptying, reducing appetite signaling in the hypothalamus, and improving glycemic control. It is not available over the counter anywhere in the United States.

In the STEP-1 trial (N=1,961), participants receiving semaglutide 2.4 mg lost a mean 14.9% of body weight at 68 weeks, compared with 2.4% in the placebo group [1]. That magnitude of weight reduction had previously been achievable only through bariatric surgery for most patients. The FDA prescribing label classifies Wegovy as prescription-only, meaning a licensed prescriber must evaluate the patient, confirm eligibility, and write the order before any pharmacy can dispense it [2].

Because Wegovy is a subcutaneous injection administered once weekly with a prefilled pen, the prescriber also needs to verify that the patient can self-inject safely and understands the 16-week dose-escalation schedule: 0.25 mg for weeks 1 through 4 to 0.5 mg for weeks 5 through 8 to 1.0 mg for weeks 9 through 12 to 1.7 mg for weeks 13 through 16, then the maintenance dose of 2.4 mg from week 17 onward [2].

Who Can Prescribe Wegovy in Florida?

Any Florida-licensed prescriber with authority to write for prescription medications can prescribe Wegovy. That includes physicians (MD and DO), advanced practice registered nurses (APRNs, including nurse practitioners), and physician assistants (PAs). Florida granted autonomous prescribing authority to APRNs in 2020 under HB 607, which means NPs in the state can prescribe Wegovy independently, without a supervising physician co-signature [3].

PAs in Florida still practice under a supervisory protocol with a physician, but their scope includes prescribing legend drugs and most controlled substances. Since semaglutide is not a scheduled controlled substance, a PA's supervisory agreement typically permits Wegovy prescriptions without additional approval steps.

The practical implication: patients do not need to see an endocrinologist or obesity medicine specialist. A primary care NP or PA at a walk-in clinic can write the prescription as long as the patient meets BMI criteria (BMI ≥30, or ≥27 with a comorbidity such as hypertension, type 2 diabetes, or dyslipidemia) and the prescriber documents a clinical assessment [2].

Telehealth Access to Wegovy in Florida

Florida law permits telehealth prescribing for Wegovy. The state's telehealth statute (F.S. § 456.47) requires that the prescribing provider hold a Florida license or be registered through the Interstate Medical Licensure Compact, that the encounter include a real-time audiovisual component for the initial visit, and that the provider establish a patient-provider relationship before issuing a prescription [4]. Follow-up visits can occur via asynchronous messaging in many platforms.

Several telehealth platforms now operate in Florida that focus on GLP-1 prescriptions. A typical workflow looks like this:

1. Online intake. The patient completes a medical history questionnaire, uploads recent lab work (or orders labs through the platform), and provides height, weight, and a list of current medications.
2. Synchronous video visit. A Florida-licensed prescriber reviews the intake, discusses risks and benefits, confirms BMI eligibility, and writes the Wegovy prescription.
3. Pharmacy routing. The prescription is sent electronically to a retail pharmacy (CVS, Walgreens, Publix) or a specialty/mail-order pharmacy.
4. Ongoing monitoring. Monthly or bimonthly check-ins track weight, side effects, and dose escalation.

Turnaround from intake to prescription is often 24 to 72 hours. Actual delivery of the medication depends on pharmacy stock and insurance processing, which can add 3 to 14 days (see the prior authorization section below).

The American Telemedicine Association's 2023 practice guidelines recommend that telehealth obesity-medicine visits include screening for contraindications such as personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, and pancreatitis [5]. Florida-based prescribers are expected to follow these screening steps regardless of whether the visit occurs in person or over video.

Insurance Coverage and Prior Authorization in Florida

Commercial insurance plans in Florida increasingly cover Wegovy, but nearly all require prior authorization (PA). According to the Endocrine Society's 2024 position statement on anti-obesity medication coverage, "prior authorization remains the single largest barrier to GLP-1 receptor agonist access for eligible patients in the United States" [6]. Florida is no exception.

A typical PA submission for Wegovy in Florida requires:

• Documented BMI of 30 or greater (or 27 or greater with a qualifying comorbidity) from a clinical visit within the past 90 days.
• Evidence of lifestyle intervention. Most insurers want documentation that the patient has attempted diet and exercise counseling. Some plans specify a 3-to-6-month supervised program, though the 2022 American Gastroenterological Association guideline recommends pharmacotherapy alongside (not after) lifestyle interventions [7].
• Failure of prior therapies. Certain plans require the patient to have tried and failed at least one other weight-management medication (phentermine, phentermine-topiramate, naltrexone-bupropion, or orlistat) before approving Wegovy.
• Prescriber notes indicating the absence of contraindications (medullary thyroid carcinoma history, MEN 2, pregnancy, or severe GI disease).

PA turnaround is typically 5 to 10 business days. If denied, most plans allow a peer-to-peer review. The prescriber calls the insurer's medical director to argue clinical necessity. About 40% to 60% of initial GLP-1 PA denials are overturned on appeal, according to data compiled by the Obesity Medicine Association [8].

Florida Medicaid does not cover Wegovy for chronic weight management. Coverage exists only under the type 2 diabetes indication (Ozempic, the lower-dose semaglutide formulation). Patients on Florida Medicaid who need semaglutide specifically for weight loss will need to explore cash-pay options, manufacturer savings programs, or compounded alternatives.

What Labs Are Required Before Starting Wegovy in Florida?

No single lab panel is mandated by the FDA for Wegovy initiation, but most Florida prescribers order baseline labs to rule out contraindications and establish metabolic benchmarks. A standard pre-Wegovy lab set includes:

• HbA1c and fasting glucose. Screens for undiagnosed type 2 diabetes or prediabetes. In STEP-1, 43.7% of participants had prediabetes at baseline, and semaglutide reduced progression to type 2 diabetes by 80% over 68 weeks [1].
• Lipid panel. Establishes cardiovascular risk. Semaglutide 2.4 mg reduced triglycerides by approximately 12% and improved HDL in STEP-1 [1].
• Comprehensive metabolic panel (CMP). Evaluates kidney and liver function. While semaglutide is not nephrotoxic, patients with eGFR <15 mL/min/1.73 m² have limited safety data [2].
• Thyroid function tests (TSH, free T4). The Wegovy label carries a boxed warning about thyroid C-cell tumors observed in rodents at supratherapeutic doses. Although no causal link has been confirmed in humans, prescribers typically document baseline thyroid status [2].
• Lipase and amylase. Optional but recommended by some obesity medicine specialists to establish a baseline before a drug class associated with rare pancreatitis events.

Some telehealth platforms partner with Quest Diagnostics or Labcorp locations throughout Florida for convenient lab draws. Others accept labs drawn within the prior 6 to 12 months if results are within normal ranges.

503A Compounding Pharmacies in Florida

Florida-licensed 503A compounding pharmacies can prepare compounded semaglutide under certain conditions. A 503A pharmacy compounds medications pursuant to individual patient prescriptions, under the supervision of a licensed pharmacist, and subject to Florida Board of Pharmacy regulations (Chapter 465, F.S.) and FDA guidance [8].

There are two important distinctions patients should understand:

Compounded semaglutide is not Wegovy. Compounded preparations use semaglutide base powder sourced from FDA-registered suppliers, but the final product is not FDA-approved, not manufactured by Novo Nordisk, and not subject to the same stability testing as the branded product. The FDA's 2023 guidance on compounded GLP-1 receptor agonists explicitly states that compounded versions "have not been found by FDA to be safe, effective, and manufactured in accordance with federal quality standards" [9].

When is compounding permitted? Under federal law, a 503A pharmacy can compound a drug that is commercially available only if the prescriber documents a clinical difference for the individual patient (for example, an allergy to an inactive ingredient in the branded product, or a need for a dose not commercially available). During periods of official FDA shortage, compounding is more broadly permitted. Florida's Board of Pharmacy maintains strict oversight, including unannounced inspections and sterility testing requirements for all sterile injectable compounds.

Patients considering compounded semaglutide should confirm that the pharmacy is licensed by the Florida Board of Pharmacy, that the semaglutide source is from an FDA-registered facility, and that the pharmacy conducts third-party potency and sterility testing on every batch.

Cost of Wegovy in Florida Without Insurance

The wholesale acquisition cost (WAC) of Wegovy is approximately $1,349 per month for the maintenance dose (2.4 mg, four prefilled pens). Retail pricing at Florida pharmacies varies:

• CVS and Walgreens typically list Wegovy between $1,300 and $1,500 per 28-day supply without insurance.
• Publix and Costco pharmacies may offer slightly lower pricing through negotiated wholesale agreements, but savings are usually modest ($50 to $100).
• Specialty mail-order pharmacies sometimes provide a lower per-unit cost, particularly with 90-day fills.

Novo Nordisk offers a manufacturer savings card that can reduce copays to as low as $0 for commercially insured patients whose plans cover Wegovy, with a maximum benefit of $500 per 28-day fill. The savings card does not apply to government-funded plans (Medicare, Medicaid, Tricare). Cash-pay patients without any insurance coverage can sometimes negotiate a self-pay rate through independent pharmacies, but the price rarely drops below $1,000 per month for brand-name Wegovy.

Compounded semaglutide from Florida 503A pharmacies typically costs between $200 and $500 per month, depending on the dose and the pharmacy. This price difference drives significant patient interest in compounding, but the quality and regulatory considerations discussed above apply.

How Long Until You Receive Wegovy After a Florida Prescription?

Timeline varies based on the prescribing channel and insurance status. A realistic breakdown:

• Cash-pay with telehealth, no PA needed: prescription written within 24 to 72 hours of the video visit. If the pharmacy has stock, pickup or delivery within 1 to 3 business days. Total: 2 to 6 days.
• Commercial insurance with PA: prescription written within 24 to 72 hours. PA submission adds 5 to 10 business days. If approved on first attempt, pharmacy fulfillment adds 1 to 5 days. Total: 7 to 18 days. If denied and appealed, add another 10 to 20 business days.
• Compounded semaglutide: most Florida 503A pharmacies ship within 3 to 7 business days after receiving the prescription, assuming the compound is already in production batches.

Stock availability has improved since the acute Wegovy shortages of 2022 and 2023. Novo Nordisk reported in its Q4 2024 earnings call that all dose strengths of Wegovy were available without supply constraints in the U.S. market [10]. Florida patients should still call their preferred pharmacy to confirm stock before the prescriber sends the electronic prescription.

Transferring an Existing Wegovy Prescription to Florida

Patients relocating to Florida or snowbirds splitting time between states can transfer an active Wegovy prescription. Florida Statute 465.025 permits the transfer of prescriptions from any U.S. state, provided the transferring and receiving pharmacies both document the transfer and the prescription has remaining refills.

The process:

1. Call the new Florida pharmacy with the name and phone number of the out-of-state pharmacy that currently holds the prescription.
2. The Florida pharmacist contacts the originating pharmacy to complete the transfer electronically or by phone.
3. If the prescription is for a 90-day supply with refills, the remaining fills transfer intact.

One caveat: if the patient's insurer changes due to the move (for example, switching from a New York employer plan to a Florida marketplace plan), a new prior authorization may be required under the new plan's formulary.

According to Dr. Caroline Apovian, co-director of the Center for Weight Management and Metabolic Surgery at Brigham and Women's Hospital, "Continuity of GLP-1 therapy is clinically important. Interruptions of even two to four weeks can lead to partial weight regain and return of appetite signaling" [11]. Patients planning a move should initiate the transfer process at least two weeks before their current supply runs out.

Safety Considerations Specific to Florida's Climate

Florida's heat presents a genuine storage concern for Wegovy. Unused Wegovy pens must be refrigerated at 36°F to 46°F (2°C to 8°C). Once in use, a pen can be kept at room temperature (up to 86°F / 30°C) for up to 28 days [2]. Florida summer temperatures regularly exceed 90°F outdoors and in parked cars.

The Endocrine Society's 2023 injectable medication storage advisory warns that "exposure to temperatures above 86°F for more than 30 minutes may degrade peptide-based injectables, reducing efficacy without visible changes to the solution" [12]. Patients should:

• Never leave Wegovy pens in a vehicle, mailbox, or outdoor delivery box during Florida summers.
• Use an insulated pouch with a cold pack when transporting pens.
• Request signature-required delivery for mail-order prescriptions to avoid pens sitting on a porch.
• Store the current pen in the refrigerator between weekly injections rather than relying on the 28-day room temperature window.